Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA
| Autor: | Jun Yin, Prateek Gulhati, Michael J. Overman, Hans-Joachim Schmoll, Qian Shi, Christophe Tournigand, Aimery de Gramont, Levi Pederson, Paulo M. Hoff, Niall Tebbut, J. Randolph Hecht, Benoist Chibaudel, Jean-Yves Douillard |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Colorectal cancer medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Carcinoembryonic antigen Stable Disease Predictive Value of Tests Internal medicine medicine Humans Neoplasm Metastasis 030304 developmental biology Aged Neoplasm Staging Randomized Controlled Trials as Topic Aged 80 and over 0303 health sciences Chemotherapy biology business.industry Area under the curve Odds ratio Articles Middle Aged medicine.disease Chemotherapy regimen Carcinoembryonic Antigen ROC Curve 030220 oncology & carcinogenesis biology.protein Disease Progression Female business Colorectal Neoplasms Progressive disease |
| Zdroj: | J Natl Cancer Inst |
| Popis: | Background Carcinoembryonic antigen (CEA) levels are used in conjunction with imaging to monitor response to systemic therapy in metastatic colorectal cancer (mCRC). We sought to identify a threshold for CEA change from baseline to predict progressive disease (PD) in mCRC patients receiving first-line therapy. Methods Patients from trials collected in the ARCAD database were included if baseline CEA was at least 10 ng/mL and repeat CEA was available within 14 days of first restaging scan. Optimal cutoffs for CEA change were identified by receiver operating characteristic analysis. Prediction performance of cutoffs was evaluated by sensitivity, specificity, and negative predictive value. Analyses were conducted by treatment class: chemotherapy alone, chemotherapy with anti-VEGF antibody, and chemotherapy with anti-EGFR antibody. Results A total of 2643 mCRC patients treated with systemic therapy were included. Median percent change of CEA from baseline to first restaging for patients with complete response, partial response, or stable disease (non-PD) and PD was −53.1% and +23.6% for chemotherapy alone (n = 957) and −71.7% and −45.3% for chemotherapy with anti-VEGF antibody (n = 1355). The optimal area under the curve cutoff for differentiating PD from non-PD on first restaging was −7.5% for chemotherapy alone and −62.0% for chemotherapy with anti-VEGF antibody; chemotherapy alone, adjusted odds ratio = 6.51 (95% CI = 3.31 to 12.83, P Conclusions Change in CEA from baseline to first restaging can accurately predict non-progression and correlates with long-term outcomes in patients receiving systemic chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|